ArticleACS omega2025
Carboxymethyl Cellulose-Encapsulated Chromium-Trithiocyanuric Acid Metal-Organic Framework for Sustained Ibuprofen Delivery: Synthesis, Characterization, Swelling, In Vitro Studies, and Cytotoxicity Analysis on A549 Cell Lines.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports a novel ibuprofen (IBU) drug delivery system using a chromium-trithiocyanuric acid metal-organic framework (Cr-MOF) encapsulated with a biodegradable, nontoxic carboxymethyl cellulose (CMC) for sustained release of ibuprofen (IBU) drug. The chromium metal-organic framework (MOF) was synthesized via the solvothermal method in a mixture of solvents in acidic conditions, followed by loading with the ibuprofen drug (Cr-MOF@IBU). Cr-MOF@IBU was further encapsulated with the CMC polymer and cross-linked with ferric chloride to form CMC/Cr-MOF@IBU hydrogel beads. Different characterization techniques were used, such as FT-IR, field emission scanning electron microscopy (FE-SEM), energy-dispersive X-ray spectroscopy (EDX), X-ray diffraction (XRD), BET, and UV-vis spectroscopy, to confirm the successful synthesis and drug loading. pH responsiveness of CMC/Cr-MOF@IBU hydrogel beads demonstrated by the swelling studies confirmed the optimal swelling in a mimicked gastrointestinal environment. The BET analysis further confirmed a significant decrease in surface area after drug loading. An in vitro drug delivery study indicated that controlled and sustained drug delivery was important for better efficacy and reducing the side effects of the drug. The cytotoxicity studies of A549 cell lines revealed the improved biocompatibility and lower toxicity of encapsulated CMC/Cr-MOF@IBU compared to Cr-MOF. This study highlights the potential of CMC/Cr-MOF@IBU as an efficient and effective drug delivery vehicle for the sustained and controlled release of ibuprofen.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.